9th International MDM2 Workshop
9th International MDM2 Workshop
Don CeSar Hotel, St. Pete Beach, Florida U.S.A
November 4-7, 2018
9th International MDM2 Workshop Topics
MDM2 and MDMX in stress response
Regulation of MDM2 and MDMX
Mouse models of MDM2 and MDMX
MDM2 and MDMX control of p53
p53-independent roles for MDM2 and MDMX
MDM2, MDMX and p53 as therapeutic targets
MDM2 and MDMX in human disease
| 2:00 PM | 6:30 PM | Registration | |
| 6:30 PM | 6:45 PM | Welcome Chen, Cleveland, Flores |
|
| 6:45 PM | 7:00 PM |
Opening Remarks Sir David Lane |
|
| 7:00 PM | 7:50 PM |
Keynote talk 1
|
|
| 7:50 PM | 9:30 PM | Reception |
| 7:00 AM | 8:00 AM | Breakfast | |
| 8:00 AM | 8:50 AM |
Keynote talk 2 Carol Prives
|
|
| 8:50 AM | 9:15 AM | Sir David Lane. Title TBD | |
| 9:15 AM | 9:40 AM |
Aart Jochemsen. Novel oncogenic function of Mdmx: inhibition of FOXO tumor suppressor activity |
|
| 9:40 AM | 10:05 AM | Hua Lu. New Regulators of the MDM2-p53 Loop | |
| 10:05 AM | 10:25 AM | Coffee break | |
| 10:25 AM | 10:50 AM | Wei Gu. Dissecting a novel pathway in p53-mediated tumor suppression | |
| 10:50 AM | 11:15 AM | Ygal Haupt. Targeting MDM4 in prostate and breast cancers: does p53 status matter? | |
| 11:15 AM | 11:40 AM | Matthias Dobbelstein. Control of DNA replication forks - p53, Mdm2, and chromatin modifications | |
| 11:40 AM | 12:05 AM | Xinbin Chen. The role of the p53-Mdm2-FDXR loop in cellular iron homeostasis | |
| 12:05 PM | 1:00 PM | Lunch | |
| 1:00 PM | 2:00 PM | Poster session+coffee break | |
| 2:00 PM | 2:25 PM | Laura Attardi. Deconstructing the Phenotypic Complexity Underlying p53-Associated Developmental Syndromes | |
| 2:25 PM | 2:50 PM | Elsa Flores. Therapeutic implications of cross talk between the p53 family and mdm2-like proteins | |
| 2:50 PM | 3:15 PM | Ute Moll. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion | |
| 3:15 PM | 3:40 PM | Franck Toledo. p53 signalling in bone marrow failure syndromes | |
| 3:40 PM | 3:55 PM | Coffee break | |
| 3:55 PM | 4:20 PM | Jim Manfredi. Regulation of mitosis by p53 and Mdm2 in vivo | |
| 4:20 PM | 4:45 PM | Yanping Zhang. In vivo, MDMX is essential in MDM2 mediated p53 degradation | |
| 4:45 PM | 5:00 PM | John Parant. Defining the mechanism of p53 tumor suppression through MDM2 null embryonic lethality | |
| 5:00 PM | 5:15 PM | Erwin Van Meir. BAI1 acts as a tumor suppressor in medulloblastoma by sequestering mdm2 from p53 | |
| 5:15 PM | 5:30 PM | Wenwei Hu. p53 codon 72 polymorphism affects aging and longevity in mouse models | |
| 6:15 PM | 10:15 PM | Bus to dinner cruise |
| 7:00 AM | 8:00 AM | Breakfast |
| 8:00 AM | 8:25 AM | Joaquin Espinosa. Novel mechanisms defining the cellular response to MDM2 inhibitors |
| 8:25 AM | 8:50 AM | Zhixiong Xiao. MDMX targets retinoblastoma protein in regulation of cellular senescence and embryonic stem cell differentiation |
| 8:50 AM | 9:15 AM | Danny Huang. E3-independent function of MDM2 in p53 regulation |
| 9:15 AM | 9:30 AM | Gary Daughdrill. Protein disorder controls the p53 network |
| 9:30 AM | 9:45 AM | Ashish Lal. A novel circular RNA from the MDM2 locus facilitates cell cycle progression by suppressing p53 levels |
| 9:45 AM | 10:05 AM | Coffee break |
| 10:05 AM | 10:30 AM | Laetitia Linares. MDM2 and Metabolism: new therapeutic strategies for liposarcoma |
| 10:30 AM | 10:55 AM | Zhaohui Feng. p53 target E3 ubiquitin ligase Parkin inhibits glycolysis and cancer metastasis |
| 10:55 AM | 11:10 AM | James DeCaprio. Dual Inhibition of MDM2 and MDM4 in Virus-Positive Merkel Cell Carcinoma Enhances the p53 Response |
| 11:10 AM | 11:25 AM | Steven Grossman. DBC1 stabilizes p53 via inhibition of CBP-dependent p53 polyubiquitination |
| 11:25 AM | 11:40 AM | Lindsey Mayo. Mdm2 promotes Angiogenesis through the regulation of pVHL |
| 12:00 PM | 1:00 PM | Lunch |
| 1:00 PM | 2:00 PM | Poster session+coffee break |
| 2:00 PM | 2:25 PM | Benjamin Beckermann. Title TBD |
| 2:25 PM | 2:50 PM | Michael Andreeff. MDM2 as Therapeutic Target in Leukemias |
| 2:50 PM | 3:15 PM | Klas Wiman. Cancer therapy by targeting missense and nonsense mutant p53 |
| 3:15 PM | 3:40 PM | David Sallman. Evolving clinical data on APR-246 in TP53 mutant myelodysplastic syndrome and acute myeloid leukemia |
| 3:40 PM | 3:55 PM | Coffee break |
| 3:55 PM | 4:20 PM | Manuel Aivado. Dual inhibition of MDMX and MDM2 with the stapled alpha-helical peptide ALRN6924 |
| 4:20 PM | 4:45 PM | Shaomeng Wang. Discovery of Highly Potent and Efficacious PROTAC MDM2 Degraders |
| 4:45 PM | 5:10 PM | Ruiwen Zhang. Dual NAFT1 and MDM2 inhibitors for Cancer Therapy |
| 5:10 PM | 5:25 PM | Wuyuan Lu. Peptide activators of p53 for cancer therapy |
| 5:25 PM | 6:30 PM | Break |
| 6:30 PM | 9:30 PM | Workshop dinner |
| 7:00 AM | 8:00 AM | Breakfast |
| 8:00 AM | 8:25 AM | Zhimin Yuan. A critical role of JNK/MDMX-dependent p53 inhibition in HFD-induced metabolic disorders |
| 8:25 AM | 8:50 AM | Christine Eischen. Targeting Mdm2 as a novel treatment for p53-inactivated cancers |
| 8:50 AM | 9:15 AM | Galina Selivanova. Unraveling the mechanisms of action of p53-activating compounds |
| 9:15 AM | 9:30 AM | Loren Walensky. Reactivation of p53-mediated apoptosis in pediatric cancers by a stapled peptide inhibitor of HDM2 and HDMX |
| 9:30 AM | 9:50 AM | Coffee break |
| 9:50 AM | 10:15 AM | Robin Fahraeus. MDM2 and the Epstein-Barr virus: A blast from the past with an oncogenic mRNA in the cast |
| 10:15 AM | 10:40 AM | Jill Bargonetti. Context Dependent Roles of MDMX (MDM4) and MDM2 in Breast Cancer |
| 10:40 AM | 11:05 AM | Jiandong Chen. Tumor-derived CK1 alpha mutations enhance MDMX inhibition of p53 |
| 11:05 AM | 11:20 AM | Dawn Chandler. MDM2 alternative splicing is regulated by microRNA binding: A novel pathway of MDM2 regulation |
| 11:20 AM | 11:55 PM | Arnold Levine. Meeting summary |
| 12:00 PM | 1:00 PM | Lunch and departure |